Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWK007 in Duchenne Muscular Dystrophy (DMD)
NCT06114056Phase 1Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2024
- Primary completion
- Nov 2029
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JWK007 in Duchenne muscular dystrophy (DMD), sponsored by West China Hospital of Sichuan University. Primary endpoint: Adverse Events at 5 years. Started Jan 2024; status: active, not recruiting.
02
Drugs
JWK007
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06114056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114056.